Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00420
|
|||||
| Drug Name |
Nelfinavir
|
|||||
| Synonyms |
ARV-SR0121; NFV; Nelfinavir (SARS infection); Nelfinavir (SARS infection), aRigen; SARS therapy, aRigen; Viracept (SARS infection), aRigen
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Sars coronavirus infections [ICD11: 1D92] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C32H45N3O4S
|
|||||
| Canonical SMILES |
CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O
|
|||||
| InChI |
InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1
|
|||||
| InChIKey |
QAGYKUNXZHXKMR-HKWSIXNMSA-N
|
|||||
| CAS Number |
CAS 159989-64-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 567.8 | Topological Polar Surface Area | 127 | ||
| Heavy Atom Count | 40 | Rotatable Bond Count | 10 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
5.7
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
ChEBI:7496
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Nelfinavir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
| 3 | Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005 Dec 1;192(11):1931-42. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.